title: [Preclinical biomarker research and patient stratification of molecular target agents: the anti-angiogenic inhibitor Lenvatinib mesylate (E7080)].
authors.forename: Junji
authors.initials: J
authors.lastname: Matsui
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Funahashi
mesh_terms: D020533:Angiogenesis Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D014408:Biomarkers, Tumor; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D058990:Molecular Targeted Therapy; D009154:Mutation; D009369:Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000235:genetics; D051059:PTEN Phosphohydrolase / Q000235:genetics; D010671:Phenylurea Compounds / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D057285:Precision Medicine; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011804:Quinolines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D012878:Skin Neoplasms / Q000188:drug therapy; D057170:Translational Research, Biomedical / Q000639:trends
chemical_list: D020533:Angiogenesis Inhibitors; D014408:Biomarkers, Tumor; D010671:Phenylurea Compounds; D011804:Quinolines; D040262:Receptors, Vascular Endothelial Growth Factor; D048493:Proto-Oncogene Proteins B-raf; D051059:PTEN Phosphohydrolase; C531958:lenvatinib